The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Japan Society of Generic Medicines Calls for 80% Generic Drug Share by Volume within 5 Years
March 8, 2013
-
BUSINESS Ajinomoto to Acquire US Contract Biologic Manufacturer Althea
March 7, 2013
-
REGULATORY MHLW Approves 45 New Compounds in 2012: Mr Akagawa of PFSB
March 6, 2013
-
BUSINESS 2 SGLT-2 Inhibitors to Be Filed for Approval without Concurrent-Use Restrictions
March 5, 2013
-
BUSINESS Pfizer Positive about In-Licensing Other Firms’ Long-Listed Drugs: VP Matsumori
March 5, 2013
-
REGULATORY Lawmakers Organizing Non-Partisan Group to Break Deadlock on Establishment of 3rd-Party Drug Administration Watchdog Organization
March 5, 2013
-
BUSINESS Pfizer Japan’s Ethical Drug Sales Dip 4.2% on Lipitor Patent Expiry: FY2012 Earnings
March 4, 2013
-
BUSINESS ARB Sales Apparently Peak Out in Japan Antihypertensive Market
March 1, 2013
-
REGULATORY 5 Years Too Long to Achieve Reference Generic Share Target of 60%: Bill Payer Reps at CSIMC Subcommittee
February 28, 2013
-
ORGANIZATION Relationships with Doctors Unchanged after Stricter Rules on Entertainment: Maker FTC Survey
February 27, 2013
-
REGULATORY JMACCT Revamps Database of Clinical Trial Institutions; Details Now Available Online
February 27, 2013
-
BUSINESS Takeda Recalling Renal Anemia Drug Omontys in US after Death Reports
February 26, 2013
-
ORGANIZATION TPP Hoped to Set Standard for Global IP Protection Rules: PhRMA Japan Rep. Wolf
February 25, 2013
-
BUSINESS LEO Pharma of Denmark to Fully Enter Psoriasis Market in Japan in 2014
February 22, 2013
-
ORGANIZATION JPMA’s New Code of Practice to Take Effect in April; Transparency in Relations with Wholesalers to Be One Focus
February 22, 2013
-
ORGANIZATION Osaka-Based NPO to Take on Outsourcing of GMP Compliance Audit on Drug Substance Makers
February 21, 2013
-
BUSINESS DSP Targets Sales of 450 Billion Yen in FY2017 by Making Latuda Blockbuster
February 19, 2013
-
BUSINESS Kowa Says Listing Application for Livalo Generic “Won’t Be Filed”; Possibility Nixed for 1st AG in Japan
February 18, 2013
-
BUSINESS Daiichi Sankyo to Launch New Firm for Duchenne Muscular Dystrophy Therapy Jointly with Govt-Backed Fund
February 15, 2013
-
BUSINESS AZ Takes Over GLP-1 Receptor Agonist Bydureon from Eli Lilly in Japan
February 14, 2013
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…